Volume 13, Number 3—March 2007
Research
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
N. Sarita Shah*1
, Abigail Wright†, Gill-Han Bai‡2, Lucia Barrera§2, Fadila Boulahbal¶2, Nuria Martín-Casabona#2, Francis Drobniewski**2, Chris Gilpin††2, Marta Havelkovᇇ2, Rosario Lepe§§2, Richard Lumb¶¶2, Beverly Metchock*2, Françoise Portaels##2, Maria Filomena Rodrigues***2, Sabine Rüsch-Gerdes†††2, Armand Van Deun##2, Veronique Vincent‡‡‡2, Kayla Laserson*, Charles Wells*, and J. Peter Cegielski*
, Abigail Wright†, Gill-Han Bai‡2, Lucia Barrera§2, Fadila Boulahbal¶2, Nuria Martín-Casabona#2, Francis Drobniewski**2, Chris Gilpin††2, Marta Havelkovᇇ2, Rosario Lepe§§2, Richard Lumb¶¶2, Beverly Metchock*2, Françoise Portaels##2, Maria Filomena Rodrigues***2, Sabine Rüsch-Gerdes†††2, Armand Van Deun##2, Veronique Vincent‡‡‡2, Kayla Laserson*, Charles Wells*, and J. Peter Cegielski*Table 2
Second-line–drug resistance patterns for Mycobacterium tuberculosis isolates, 2000–2004 (N = 17,690)*†
| Pattern | Other 13 SRLs‡ | Republic of Korea SRL‡ | ||
|---|---|---|---|---|
| (n = 5,751) | (n = 11,939) | |||
| No. tested | No. (%) resistant | No. tested | No. (%) resistant | |
| Any resistance | 5,751 | 1,237 (21.5) | 11,939 | 849 (7.1) |
| Aminoglycosides§ | 5,620 | 489 (8.7) | 11,939 | 227 (1.9) |
| Capreomycin | 4,347 | 197 (4.5) | 11,939 | 122 (1.0) |
| Fluoroquinolones | 5,580 | 298 (5.3) | 11,939 | 524 (4.4) |
| Thioamides | 5,131 | 556 (10.8) | 11,939 | 259 (2.2) |
| Cycloserine | 2,715 | 70 (2.6) | 11,939 | 80 (0.7) |
| Para-aminosalicylic acid | 3,571 | 262 (7.3) | 11,939 | 403 (3.4) |
*SRLs, Supranational Reference Laboratories.
†Not all isolates were tested for each second-line–drug class (with the exception of the Republic of Korea SRL), so results are reported as a proportion of isolates tested to the specified class of drugs.
‡Cells are not mutually exclusive.
§Other than streptomycin (e.g., kanamycin, amikacin).
